Peter J. Goebell

3.0k total citations
87 papers, 1.6k citations indexed

About

Peter J. Goebell is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Cancer Research. According to data from OpenAlex, Peter J. Goebell has authored 87 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 34 papers in Surgery and 29 papers in Cancer Research. Recurrent topics in Peter J. Goebell's work include Renal cell carcinoma treatment (32 papers), Bladder and Urothelial Cancer Treatments (29 papers) and Cancer Genomics and Diagnostics (22 papers). Peter J. Goebell is often cited by papers focused on Renal cell carcinoma treatment (32 papers), Bladder and Urothelial Cancer Treatments (29 papers) and Cancer Genomics and Diagnostics (22 papers). Peter J. Goebell collaborates with scholars based in Germany, United States and Netherlands. Peter J. Goebell's co-authors include Bernd J. Schmitz‐Dräger, Bernd Wullich, H. Barton Grossman, Torsten Kuwert, Olaf Prante, Philipp Ritt, Christian Schmidkonz, Aldo Bono, Tobias Bäuerle and Michael Uder and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Peter J. Goebell

84 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter J. Goebell Germany 19 822 702 499 375 312 87 1.6k
Darrel Drachenberg Canada 19 773 0.9× 677 1.0× 438 0.9× 378 1.0× 119 0.4× 99 1.5k
Jean‐Baptiste Lattouf Canada 24 670 0.8× 718 1.0× 376 0.8× 267 0.7× 144 0.5× 93 1.5k
Koji Mitsuzuka Japan 22 761 0.9× 333 0.5× 424 0.8× 215 0.6× 115 0.4× 117 1.5k
Carsten Kempkensteffen Germany 27 901 1.1× 470 0.7× 1.1k 2.2× 236 0.6× 172 0.6× 102 2.2k
Guillaume Ploussard France 34 2.5k 3.0× 875 1.2× 381 0.8× 503 1.3× 329 1.1× 112 3.2k
Robert Given United States 19 1.7k 2.1× 401 0.6× 262 0.5× 432 1.2× 555 1.8× 57 2.2k
Vito Cucchiara Italy 27 1.3k 1.6× 524 0.7× 268 0.5× 248 0.7× 267 0.9× 69 1.9k
Enrique Gallardo Spain 18 621 0.8× 571 0.8× 500 1.0× 480 1.3× 73 0.2× 90 1.6k
Albert Font Spain 22 874 1.1× 318 0.5× 498 1.0× 720 1.9× 141 0.5× 75 1.7k
Bimal Bhindi Canada 23 1.2k 1.5× 710 1.0× 555 1.1× 486 1.3× 169 0.5× 95 1.9k

Countries citing papers authored by Peter J. Goebell

Since Specialization
Citations

This map shows the geographic impact of Peter J. Goebell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Goebell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Goebell more than expected).

Fields of papers citing papers by Peter J. Goebell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Goebell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Goebell. The network helps show where Peter J. Goebell may publish in the future.

Co-authorship network of co-authors of Peter J. Goebell

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Goebell. A scholar is included among the top collaborators of Peter J. Goebell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Goebell. Peter J. Goebell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Powles, T.B., Christof Vulsteke, M. Gross Goupil, et al.. (2024). LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis. Annals of Oncology. 35. S1505–S1507. 4 indexed citations
2.
Goebell, Peter J., et al.. (2024). Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncology. 20(14). 903–918. 15 indexed citations
3.
Meidenbauer, Norbert, Frank Kunath, Peter J. Goebell, et al.. (2022). New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial. Journal of Clinical Medicine. 11(15). 4558–4558. 5 indexed citations
4.
Lieb, Verena, Siegfried Hauch, Michael Gombert, et al.. (2022). Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients. Cells. 11(22). 3618–3618. 1 indexed citations
5.
Lieb, Verena, Siegfried Hauch, Michael Gombert, et al.. (2021). Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients. Cells. 10(11). 3223–3223. 3 indexed citations
6.
Goebell, Peter J., Christian Doehn, Norbert Marschner, et al.. (2019). Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study. Oncology Research and Treatment. 42(1-2). 57–66. 2 indexed citations
7.
Goebell, Peter J., et al.. (2019). Assessments vor Operationen. Der Urologe. 58(4). 373–380. 1 indexed citations
8.
9.
Bedke, Jens, Manfred Welslau, Martin Boegemann, et al.. (2017). Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape. Annals of Oncology. 28. v318–v319. 1 indexed citations
10.
Marschner, Norbert, Michael Staehler, Lothar Müller, et al.. (2016). Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry. Clinical Genitourinary Cancer. 15(2). e209–e215. 44 indexed citations
11.
12.
13.
Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2015). SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology. 68(5). 837–847. 111 indexed citations
14.
Bergmann, Lothar, Christian Doehn, Thomas Steiner, et al.. (2015). Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study. BMC Cancer. 15(1). 303–303. 22 indexed citations
15.
Kamat, Ashish M., Antonia Vlahou, John A. Taylor, et al.. (2014). Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 32(7). 1069–1077. 27 indexed citations
16.
Rogler, Anja, Eileen Socher, Elke Nolte, et al.. (2013). Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.. PubMed. 6(10). 1984–98. 15 indexed citations
17.
Keck, Bastian, Sven Wach, Peter J. Goebell, et al.. (2013). SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer. Annals of Surgical Oncology. 20(11). 3669–3674. 10 indexed citations
18.
Kunath, Frank, Steffen Krause, Bernd Wullich, et al.. (2013). Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov. BMC Urology. 13(1). 56–56. 12 indexed citations
19.
Goebell, Peter J., Susan L. Groshen, & Bernd J. Schmitz‐Dräger. (2008). Guidelines for development of diagnostic markers in bladder cancer. World Journal of Urology. 26(1). 5–11. 35 indexed citations
20.
Lokeshwar, Vinata B., Tomonori Habuchi, H. Barton Grossman, et al.. (2005). Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 66(6). 35–63. 306 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Darrel Drachenberg Breakdown of academic impact, for papers by Jean‐Baptiste Lattouf Breakdown of academic impact, for papers by Koji Mitsuzuka Breakdown of academic impact, for papers by Carsten Kempkensteffen Breakdown of academic impact, for papers by Guillaume Ploussard Breakdown of academic impact, for papers by Robert Given Breakdown of academic impact, for papers by Vito Cucchiara Breakdown of academic impact, for papers by Enrique Gallardo Breakdown of academic impact, for papers by Albert Font Breakdown of academic impact, for papers by Bimal Bhindi
Rankless by CCL
2026